Elsevier

Neuropharmacology

Volume 31, Issue 7, July 1992, Pages 713-715
Neuropharmacology

Preliminary note
The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosets

https://doi.org/10.1016/0028-3908(92)90151-EGet rights and content

Abstract

Experiments in MPTP-treated non-human primates testing potential antiparkinsonian action have shown both, beneficial and adverse effects of gutamate receptor antagonists. To investigate this matter further, the novel competitive NMDA antagonist CGP40.116 was administered systemically to three adult MPTP-treated marmosets. When coadministered subcutaneously with a subthreshold dose of L-DOPA, 2 mg/kg, CGP40.116 25–250 μg/kg, increased locomotor activity. However, when administered alone, CGP40.116 had no effect on locomotor activity.

References (14)

There are more references available in the full text version of this article.

Cited by (41)

View all citing articles on Scopus
View full text